BRII-B Unveils Breakthrough Phase II Data from ENRICH and ENHANCE Studies at 2026 AASLD Annual Meeting

Stock News11-06

BRII-B (02137) has announced that the company presented end-of-treatment (EOT) and follow-up results from its Phase IIb ENRICH and ENHANCE studies in three late-breaking oral presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®, held from November 5 to 9, 2026, in Denver, Colorado, USA.

The latest results further enrich the data accumulated across five Phase II studies of BRII-179. In particular, the ENSURE, ENRICH, and ENHANCE studies, through a progressively layered research design, conducted in-depth evaluations of BRII-179's potential to activate HBV-specific immune responses and enrich participants with immune-responsive characteristics, providing a basis for the design of combination treatment regimens aimed at achieving durable hepatitis B surface antigen (HBsAg) clearance and functional cure.

In the ENSURE study Cohort 4, the potential immune activation and enrichment effects of BRII-179 were first observed: participants who had received BRII-179 treatment demonstrated higher functional cure rates, especially those who developed hepatitis B surface antibody (anti-HBs) responses. Subsequently, the ENRICH study prospectively evaluated this strategy: participants first received 12 weeks of BRII-179 treatment (administered every 3 weeks or every 2 weeks), followed by elebsiran and pegylated interferon alpha (PEG-IFNα) treatment. Across both BRII-179 dosing regimens in the ENRICH study, 41.9% of participants achieved HBsAg clearance at EOT, and 32.4% of participants maintained HBsAg clearance 24 weeks after EOT; both results were consistent with observations from the ENSURE study Cohort 4.

The ENHANCE study further evaluated how to incorporate BRII-179 into a triple combination regimen consisting of BRII-179, elebsiran, and PEG-IFNα. In Part A1, concurrent triple therapy with BRII-179, elebsiran, and PEG-IFNα achieved higher HBsAg clearance rates at EOT compared with PEG-IFNα monotherapy (25.5% vs. 10.2%, respectively), and this trend was maintained through 24 weeks after EOT (17.3% vs. 6.1%, respectively). Part A2 of the ENHANCE study evaluated a sequential combination strategy, in which BRII-179 plus elebsiran was first used for 24 weeks of immune activation, followed by elebsiran combined with a shortened 24-week course of PEG-IFNα. At EOT, 22.5% of participants achieved HBsAg clearance. Participants who developed anti-HBs responses after BRII-179 plus elebsiran immune activation (defined as anti-HBs ≥ 10 IU/L at Week 24) had higher HBsAg clearance rates at EOT compared with non-responders (30.6% vs. 15.9%, respectively). At 8 weeks after EOT, the overall HBsAg clearance rate among participants further rose to 25.0%, while the HBsAg clearance rate among anti-HBs responders rose to 33.3%. These results further reveal the immune activation effects of BRII-179 and its potential to improve responses to subsequent siRNA and PEG-IFNα combination therapy.

Both the ENRICH and ENHANCE studies observed encouraging HBsAg clearance rates among participants with higher baseline HBsAg levels. In the ENRICH study, among participants with baseline HBsAg levels above 1,000 IU/mL and up to 3,000 IU/mL, 32.1% achieved HBsAg clearance at EOT, and 20.8% maintained HBsAg clearance 24 weeks after EOT. In Part A1 of the ENHANCE study, among participants with baseline HBsAg levels above 1,000 IU/mL, those receiving triple therapy achieved HBsAg clearance rates of 24.2% at EOT and 18.2% at 24 weeks after EOT, while no participants in the PEG-IFNα monotherapy group achieved HBsAg clearance at either time point. In Part A2 of the ENHANCE study, 14.6% and 16.7% of participants in this high-baseline subgroup achieved HBsAg clearance at EOT and 8 weeks after EOT, respectively. These results support further evaluation of BRII-179-based immune activation strategies in patients with higher baseline HBsAg, a population that has historically been more difficult to achieve functional cure in.

The treatment regimens in all studies were generally safe and well tolerated. Dr. David Margolis, Chief Medical Officer of BRII-B, stated: "Our Phase IIb study results provide a more solid scientific basis for continuing to evaluate BRII-179-based immune activation and enrichment strategies. At the same time, these results also provide important insights into how to utilize BRII-179 to activate HBV-specific immunity and how to guide subsequent treatment based on early immune responses. Taken together, these findings are expected to help guide the design of future clinical studies, including research in populations with higher baseline HBsAg levels who are more difficult to achieve functional cure."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment